CN103735499B - A kind of Ulifloxacin hydrochloride eye drop and preparation method thereof - Google Patents
A kind of Ulifloxacin hydrochloride eye drop and preparation method thereof Download PDFInfo
- Publication number
- CN103735499B CN103735499B CN201310738292.4A CN201310738292A CN103735499B CN 103735499 B CN103735499 B CN 103735499B CN 201310738292 A CN201310738292 A CN 201310738292A CN 103735499 B CN103735499 B CN 103735499B
- Authority
- CN
- China
- Prior art keywords
- ulifloxacin
- hydrochloric acid
- eye drop
- water
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a kind of hydrochloric acid NM394 (Ulifloxacin) eye drop and preparation method thereof, described Ulifloxacin hydrochloride eye drop, with hydrochloric acid NM394 for raw material is directly prepared, every milliliter of hydrochloric NM394 1-5 milligram, other is ophthalmic preparation proper auxiliary materials or water for injection.Ulifloxacin hydrochloride eye drop of the present invention can effectively infect by prevention and therapy eye sensitive organism; particularly the ever-increasing Pseudomonas aeruginosa of drug resistance is at interior gram positive bacterial infection; bioavailability is high; the ophthalmic time of staying is long, and post antibiotic effect is given prominence to, and is conducive to the single dose reducing medicine; well cost is low simultaneously for therapeutic effect; production technology is convenient and simple, the cycle is short, meets large-scale production needs, is of practical significance for the ocular infection disease for the treatment of drug resistance day by day.
Description
Technical field
The present invention relates to a kind of Ulifloxacin hydrochloride eye drop and preparation method thereof, belong to pharmaceutical technology sectors.Ulifloxacin hydrochloride eye drop of the present invention can effectively infect by prevention and therapy eye sensitive organism.
Background technology
Infectious eye disease refers to a class diseases associated with inflammation of eye caused by the pathogen such as antibacterial, fungus, virus, mycoplasma, rickettsia, spirillum and parasite and appendages, it is eye commonly encountered diseases, often cause part tissue of eye to damage in various degree, can vision be had a strong impact on, even blinding.In recent years, due to a variety of causes such as environmental pollutions, infectious eye disease is in rising trend, and conditioned pathogen increases, and cause of disease kind is more, wider, and along with the application of extensive pedigree antibiotic, the drug resistance of antibacterial constantly increases.
The anatomical structure of eye and appendages thereof is special, once occur infecting, be easy to spread to deep tissues and offside, adding the factors such as the change of environmental factors, sanitary condition, body autoimmunity, the application of extensive pedigree antibiotic and the transition of bacterium living beings characteristic, there is certain difficulty in the Diagnosis and Treat of infectious eye disease.
According in Mays, 2012 such as Tianjin ophthalmologic hospital clinical laboratory Zhang Bin, antibacterial is the main pathogenic fungi of infectious eye disease, accounts for 87.73% of infectious sample.In bacteriological infection, gram positive coccus accounts for 76.03%, and staphylococcus epidermidis proportion is up to 46.15%; Gram negative bacilli accounts for 19.69%, in the majority with non-zymocyte, and wherein Pseudomonas aeruginosa accounts for 28.98% (40/138); Grain-positive bacillus accounts for 4.28%.The corneal ulcer incubation period caused by Pseudomonas aeruginosa is short, morbidity is anxious, progress is fast, very easily blinding.Pseudomonas aeruginosa in conjunctival sac secretions can be pathogenic bacterium, causes conjunctivitis; Also can be conditioned pathogen, be present in conjunctival sac, cause ocular disease when immunity of organisms is low.Aqueous humor infects Pseudomonas aeruginosa can cause endophthalmitis, and severe patient must extract eyeball.Pseudomonas aeruginosa reproductive capacity is strong, can cause breaking out with popular in hospital time serious.Analyze the drug resistance result display of infectious eye disease pathogen: the drug resistance of gram positive coccus is higher, the resistant rate of staphylococcus epidermidis to penicillin, erythromycin, oxazacillin and norfloxacin higher (>70.00%); Gram negative bacilli is based on Pseudomonas aeruginosa, and it has very high drug resistance to ampicillin/sulbactam, Fu side's Sulfamethoxazole, cefotaxime, and resistant rate reaches 100%.(Zhang Bin etc., the pathogenic distribution of infectious eye disease and drug resistance analysis, the sick magazine of Chinese clinical infection, 2012,5(4): 205-209).
Antimicrobial Resistance of Pseudomonas Aeruginosa is stronger, normal in many drug resistances, this bacterium resistance mechanism is complicated, mainly contain and produce multiple beta-lactamase, the expression of epicyte active efflux system, outer membrane protein change cause that permeability declines, the change of penicillin-binding protein and form biomembrane etc., drug resistance is existed to most of beta-Lactam antibiotic, chloromycetin, sulfonamides, rifampicin etc.Research shows that Pseudomonas aeruginosa has same resistance mechanism to fluoroquinolones, and quinolones, as levofloxacin, ciprofloxacin, lomefloxacin, declines year by year to some extent to the sensitivity of Pseudomonas aeruginosa.
Ophthalmology antibacterials kind is less, and using dosage, drug level, frequency of utilization etc. are different with intravenous drip medication.The drug resistance of antibacterial constantly increases, and the drug resistance of same antibacterial constantly changes with treatment, and experience Treatment and diagnosis is difficult to prove effective, and more and more relies on the examining report of laboratory.The antibiotic that current ophthalmology is conventional can be divided into chloromycetin (representing medicine is chloromycetin), aminoglycosides (representing medicine is gentamycin) and quinolones (to represent medicine and only have ofloxacin, ciprofloxacin, levofloxacin, norfloxacin etc. are several) etc. three major types.It is worth mentioning that current antibiotic eye drops is after long-term clinical observation, find have side effect in various degree and drug resistance phenomenon.As Chloramphenicol Eye Drop, applicating history is very long, and drug-resistant bacteria is many and antibacterial effect is obviously reduced; But also whole body hematopoietic function likely can be caused to destroy, also may can cause death time serious, all there had been such adverse effect record home and abroad.Disposable levofloxacin hydrochloride eye drops also has drug-resistant bacteria to fall through long-term utilization and makes antibacterial effect obviously low, and because fluoroquinolones is extensive at clinical departments, extensive application, Main Pathogenic Bacteria increases its resistant rate.(antibacterials are in the reasonable application of clinical ophthalmology, and Shanghai is medical, 2010,31(7 for Huashan Hospital Affiliated To Fudan Univ ophthalmology, Xiao Yiqin etc.)).
When choice for use ophthalmology antibiotic medicine, not only to consider the effectiveness of medicine, also will consider drug resistance and the safety of medicine simultaneously.Doctor treat infectious eye disease time rule on targetedly based on a kind of antibacterial drug therapy, the Drug therapy of eye bacteriological infection mainly adopts local application.In the pathogen of eye bacteriological infection, gram positive bacteria, based on staphylococcus, is secondly streptococcus, streptococcus pneumoniae etc.; Gram negative bacilli is then common with Pseudomonas aeruginosa, is secondly Bacillus proteus and escherichia coli etc.
The kind of eye bacteriological infection and other site infection of body have a great difference, and the existence of blood-ocular barrier and corneal epithelium makes antibacterials application within the eye have certain particularity.The antimicrobial spectrum of often kind of antibacterials is not identical with indication, and eye clinical diagnosis, bacteriology checking and drug sensitive test thereof can be used as the important references selecting medicine.Select antimicrobial spectrum, the antibacterial action feature that must understand medicine used during antibacterials, to select corresponding active drug.The infection not clear to pathogen should adopt extensive pedigree antibiotic or antibacterials use in conjunction.For serious ocular infection, antibacterial culturing often obtains negative findings again, and the normal therapy by rule of thumb for the treatment of is carried out.Now, medicine is selected to have notably at 2 for pathogenic bacterium: one, from the character infected and the possible pathogenic bacterium of site analysis; Its two, be the curative effect of patient medication.Medications as enough in a kind of antibacterials after 3 ~ 5 days clinical symptoms be still not improved, then should consider to use instead other may effective antibacterial drug therapy, in order to avoid affect the state of an illness adversely.So more effective, the safe eye medicinal of developing new product variety has important clinical therapeutic value for treatment eye bacteriological infection.
The international Ulifloxacin by name of NM394, the chemistry fluoro-1-methyl of 6--4-oxo-7-(1-piperazinyl)-4H-(1,3) sulfur nitrogen heterocycle also (3,2-a) quinoline-3-carboxylic acid by name, thiophene fourth pyridine-quinoline carboxylic acid derivative.
NM394 structural formula:
Hydrochloric acid NM394 is the hydrochlorate of NM394, and in body, effective ingredient is NM394:
NM394 has broad-spectrum antibacterial action to gram positive bacteria and gram negative bacteria, and all have activity to anaerobe, legionella and chlamydia etc., anti-gram-negative bacteria external activity is outstanding in fluoroquinolone.Compare with levofloxacin with ciprofloxacin, Gatifloxacin, NM394 is easier to accumulation in S. aureus L-forms, escherichia coli and Pseudomonas aeruginosa cell, and short-term bactericidal action is stronger; Particularly large Pseudomonas aeruginosa is endangered for ophthalmology, be better than ciprofloxacin, levofloxacin and Moxifloxacin.In addition, this kind also has longer post antibiotic effect, more more lasting than ciprofloxacin.Experiment in vivo and vitro all shows, NM394 is has a broad antifungal spectrum not only, and activity in vivo is strong, have excellent bactericidal action and post antibiotic effect, cytotoxicity low, move to central nervous system the advantage such as few of dividing a word with a hyphen at the end of a line.
Though NM394 has excellent antibacterial activity, but injection application also has crystalluria and injury of kidney. according to the research of IshidaS etc., the quiet note of surrounding is scheduled to last to rat, 3mg/kg dosage group does not find obvious problem, 10,30mg/kg dosage group rat water consumption and urine discharge capacity obviously increase, and find crystal material and small epithelial cells in urinary sediment thing.So, should be 3mg/kg to NOAEL (not observing the levels of drugs of the untoward reaction) dosage of rat.Be transformed into the prulifloxacin (Prulifloxacin) of oral administration after NM394 chemical modification, prulifloxacin is developed by Japanese new drug company and the joint research of Mingzhi company, and its Tabules was got permission in 2002 to go on the market in Japan.Prulifloxacin is forth generation fluoroquinolone antibacterial agent, and it is NM394 prodrug, in vivo through serum enzymatic hydrolysis, removes modification group on C7 position, obtains active component NM394.The maximum feature of NM394 has good antibacterial activity to the gram negative bacteria comprising the ever-increasing Pseudomonas aeruginosa of drug resistance.The oral rear metabolism of prulifloxacin is rapid, and in body circulation, generally can't detect original shape medicine, can only be measured to its active metabolite NM394, plasma half-life is 7.7 ~ 8.9 hours.
CN200610097346.3 discloses Prulifloxacin active body injection, and wherein this invention is directly used in intravenous NM394 injection, makes active medicine NM394 directly enter blood, plays therapeutical effect rapidly.
The NM394 hydrochloric acid that CN201010128827.2 discloses a kind of novel stabilising is preparing the application in anti-infectives, this invention is with the form direct injection of thiophene fourth pyridine quinoline carboxylic acid, improve dissolubility, improve the bioavailability of this medicine, improve therapeutic effect simultaneously.
The NM394 mesylate that CN201010133378.0 discloses a kind of novel stabilising is preparing the application in anti-infectives, and wherein this invention is with the form direct injection of thiophene fourth pyridine quinoline methanesulfonic acid hydrochlorate.CN101003540 discloses the fluoro-1-methyl of 6--4-oxo-7-(1-piperazinyl)-4H-[1,3] thiazine [3,2-a] quinoline-3-carboxylic acid mesylate and preparation method and its usage, and in patent specification, this salt pH value is about 2.90.
At present, the relevant report of the Ulifloxacin hydrochloride eye drop not yet having employing directly to prepare for raw material with hydrochloric acid NM394, does not have thiophene fourth pyridine class eye drop to declare clinical research yet and listing uses.Eye drop belongs to external preparation, all different from injection route of administration, site of action, and application process is also different; Ulifloxacin hydrochloride eye drop for this labyrinth organ of eyes disease and research and develop, from common hydrochloric acid NM394 injection materials application and require obviously different in viscosity, penetration enhancement, antibacterial etc.
Summary of the invention
The object of the invention is for current antibiotic eye drops after clinical practice for many years, find have side effect in various degree and drug resistance phenomenon, develop the Ulifloxacin hydrochloride eye drop meeting large-scale production and clinical needs.NM394 dissolubility in water is little, can wash out because local concentration is high in preparation eye drop and use procedure, directly affect the accuracy of patient's use and dosage, NM394 antibacterial ability is larger by the impact of pH in addition, so be prepared into hydrochloric acid NM394 to strengthen dissolubility, then be adjusted to best antimicrobial pH and just just can better solve preparation technique problem.
The present invention also provides the preparation method of the Ulifloxacin hydrochloride eye drop directly prepared for raw material with hydrochloric acid NM394.
Ulifloxacin hydrochloride eye drop described in the present invention, every milliliter of hydrochloric NM394 1-5 milligram, other is ophthalmic preparation proper auxiliary materials or water for injection.Ophthalmic preparation proper auxiliary materials requires see Chinese Pharmacopoeia 2010 editions two annex IG ophthalmic preparations and eye drop, annex II pharmaceutic adjuvant.The adjuvant regulating osmotic pressure, pH, viscosity and increase drug solubility and preparation stability can be added in eye drop, and antibacterial and the antioxidant of suitable concentration can be added, adjuvant used should not reduce drug effect or produce local excitation, and unless otherwise specified, eye drop should be isotonic with tear.Ophthalmic preparation adjuvant is common as follows:
(1) pH adjusting agent
Conventional has abbreviation phosphate buffer (phosphate buffer, Sharpe phosphate buffer), borate buffer (borate buffer, borate buffer solution, Palitzsch's buffer solution), lucky Fei Shi buffer, acetate buffer (Acetic acid-sodium acetate buffer, acetate buffer), hydrochloric acid, acetic acid, sodium hydroxide solution etc.
(2) osmotic pressure regulator
Conventional has sodium chloride, glucose, boric acid, Borax etc.Glycerol has adjustment and oozes the multiple actions such as adjust blood pressure, stabilizing agent, cosolvent, moisturizing.
(3) antibacterial
The antibacterial used in ophthalmic preparation should meet following requirement in principle: 1. effectiveness: antibacterial should have broad-spectrum antiseptic ability, has restraint or lethality to the breeding of antibacterial (particularly green pus bacterium) and fungus, and effect rapidly.2. safety: in the frequency of usage and concentration of clinical regulation, can not cause ocular tissue (particularly cornea) and stimulate and injury.3. stability: do not produce chemical reaction after antibacterial and the mixing of the composition such as principal agent and other adjuvants, negative effect is not caused to the pH of preparation, osmotic pressure; Antibacterial self should be more stable, heat-resisting, can preserve for a long time.The antibacterial used in current ophthalmic preparation, is nearly all difficult to meet completely these desirable requirements above.Therefore, need from antibacterial and the compatibility of principal agent and other compositions, the impact of sterilizing and stability angularly, select the antibacterial that more than As soon as possible Promising Policy requires.In addition, due to differences such as the kind of principal agent contained in ophthalmic preparation and adjuvant, pH value, the antibacterial that may pollute or fungal species, also can there is corresponding change in the valid density of required antibacterial.
General eye drop is multi-dose formulation, cannot keep aseptic, therefore need to add antibacterial after once using.Selected antibacterial answers bacteriostasis rapid, and fungistatic effect reliable (staphylococcus aureus and bacillus pyocyaneus can be killed in 1h), have suitable pH, non-stimulated to eyes, stable in properties, not with principal agent and additives generation incompatibility.Common antibacterial in ophthalmic preparation can be divided into following a few class according to its chemical constitution and character: 1. parabens (parabens), as methyl hydroxybenzoate, ethyl hydroxybenzoate etc.; 2. cationic surfactant, as benzalkonium chloride, benzalkonium bromide etc.; 3. alcohols, as chlorobutanol; 4. organic mercury class, as thimerosal, Mercury pernitrate.; 5. acids, as sorbic acid; 6. new bacteriostatic agent, polyquaternium (in the right prescription of import ophthalmic preparation tear existing use).Conventional as benzalkonium chloride, benzalkonium bromide, Benzene Chloride first azanol (0.01% ~ 0.02%), thimerosal (0.005% ~ 0.01%), phenethanol (0.5%), chlorobutanol (0.35% ~ 0.5%), methyl parahydroxybenzoate and propyl p-hydroxybenzoate mixture (methyl parahydroxybenzoate 0.03% ~ 0.1%, propyl p-hydroxybenzoate 0.01%) etc.
Single antibacterial, often because the pH value of prescription is not suitable for, or has incompatibility can not reach the object sterilized rapidly with other compositions.The antibacterial of compound is adopted to play synergism.Practice confirms that good compatibility is as follows: benzalkonium chloride and edetate sodium.Edetate sodium itself does not have bacteriostasis, but a small amount of edetate sodium can make other antibacterial strengthen the effect of bacillus pyocyaneus; Benzalkonium chloride and chlorobutanol add edetate sodium or oxybenzene esters again; Phenoxyethanol and oxybenzene esters.
(4) viscosity-controlling agent
Cry again thickening agent, prolongation of effect agent.The viscosity of suitable increase eye drop, can make medicine extended residence time within the eye, and zest also can be made to weaken.Conventional methylcellulose (mc), polyvinyl alcohol (pva), polyvidone (pvp), hypromellose, hyaluronic acid sodium etc.Some thickening agent may also have solubilising or sorbefacient effect, as hypromellose, hyaluronic acid sodium etc.
(5) other (stabilizing agent, solubilizing agent and cosolvent)
For labile drug, antioxidant and metal-chelator need be added; The medicine that dissolubility is little need add solubilizing agent or cosolvent; Macromolecular drug can add absorption enhancer when absorbing not good.
Preparation Ulifloxacin hydrochloride eye drop must consider the various factors such as physicochemical property, decides scheme in conjunction with specific experiment effect.Hydrochloric acid NM394 is off-white color or faint yellow solid, molecular formula C
16h
19cLFN
3o
3s, molecular weight 389.7, when in water, dissolubility is 25 DEG C, 59.7mg/ml is solvable, and NM394 is 2.7mg/ml genus slightly soluble.Hydrochloric acid NM394 has certain stability to 60 DEG C of high temperature, high humidity, possesses the preparation primary condition can preparing every milliliter of hydrochloric NM394 1-5 milligram, but wants comprehensive Design prescription, technique, decide scheme by specific experiment effect.
The pH value of eye drop directly affects the curative effect of stimulation to eye and medicine.Eyes are without sense of discomfort when being 5.0 ~ 9.0, pH6.0 ~ 8.0 for the pH value of normal eye tolerance, and the pH value of human body tear is 7.4, are less than 5.0 and be greater than 11.4 and have obvious irritation.The selection of pH value should take into account drug solubility, stability and to many factors such as the zests of eye.Hydrochloric acid NM394 is when pH5.5, to colon bacillus and Pseudomonas aeruginosa effect than 4-16 strong during pH7 doubly, in order to play the effect infected the Pseudomonas aeruginosa etc. of clinical refractory, increase hydrochloric acid NM394 solubility property simultaneously, Ulifloxacin hydrochloride eye drop slant acidity pH5-7 of the present invention, preferred pH5.5 ± 0.5, pH adjusting agent is selected from phosphate buffer (phosphate buffer, Sharpe phosphate buffer), boric acid series of buffer (borate buffer, borate buffer solution, Palitzsch's buffer solution), lucky Fei Shi buffer, acetate series of buffer (Acetic acid-sodium acetate buffer, acetate buffer), hydrochloric acid, acetic acid, sodium hydroxide solution.
In specific experiment, find that hydrochloric acid NM394 is soluble in water, its aqueous solution also there will be inadequate stabilization, and hydrochloric acid NM394 aqueous solution is not very stable to illumination and heating especially, can pass in time and produce some catabolites, degraded can affect the treatment and produce toxic and side effects.The compound structure of xacin-series meets hydrochloric acid, precipitation or zest side effect may be had to occur, if 2% hydrochloric acid lomefloxacin injection is at northern China low temperature crystallize, and if ciprofloxacin orally can be made injection or the irritant side effect of other preparations and to occur and unsuccessful.5mg/ml hydrochloric acid NM394 aqueous solution pH5.0 when 25 DEG C, need research to be adjusted in comparatively large-temperature range, pH is in proper states.
In order to solve series of technical, by repeatedly studying, comprehensive assessment, filters out following Ulifloxacin hydrochloride eye drop technical scheme: Ulifloxacin hydrochloride eye drop, every milliliter contains hydrochloric acid NM394 1-5 milligram, and other is suitable eye adjuvant and water for injection.Ulifloxacin hydrochloride eye drop, preferably every finished product every milliliter is containing hydrochloric acid NM394 1-5 milligram, and suitable eye adjuvant is osmotic pressure regulator 1-20 milligram, antibacterial appropriate (0.0001-5 milligram), viscosity-controlling agent 0.2-0.5 milligram and water for injection.Osmotic pressure regulator is selected from sodium chloride, glucose, boric acid, potassium chloride, glycerol; Viscosity-controlling agent is selected from methylcellulose, polyvinyl alcohol, polyvidone, hypromellose, hyaluronic acid sodium; Antibacterial is selected from benzalkonium chloride, benzalkonium bromide, thimerosal, phenethanol, chlorobutanol, parabens.Described Ulifloxacin hydrochloride eye drop pH value is 5.0-7.0, preferable ph is 5.5 ± 0.5, and described pH adjusting agent is selected from phosphate buffer (phosphate buffer, Sharpe phosphate buffer), boric acid series of buffer (borate buffer, borate buffer solution, Palitzsch's buffer solution), lucky Fei Shi buffer, acetate series of buffer (Acetic acid-sodium acetate buffer, acetate buffer), sodium acetate-borate buffer, hydrochloric acid, acetic acid, sodium hydroxide solution.
One of optimal technical scheme is: every finished product every milliliter containing hydrochloric acid NM394 2 milligrams, osmotic pressure regulator 9 milligrams, antibacterial 0.7 milligram, viscosity-controlling agent 0.35 milligram.Wherein osmotic pressure regulator is 9 milligrams, sodium chloride, glucose 12 milligrams or 4 milligrams, sodium chloride and glucose 7 milligrams of mixture; Antibacterial is methyl parahydroxybenzoate 0.5 milligram and propyl p-hydroxybenzoate 0.15 milligram; Viscosity-controlling agent is methylcellulose 0.35 milligram.Described Ulifloxacin hydrochloride eye drop pH value is 5.0-7.0, and preferable ph is 5.5 ± 0.5.PH adjusting agent is selected from phosphate buffer, borate buffer, borate buffer solution, acetate buffer solution, acetate buffer, sodium acetate-borate buffer, lucky Fei Shi buffer, hydrochloric acid, acetic acid, sodium hydroxide solution etc.
Preparation method of the present invention is with hydrochloric acid NM394 for prepared by raw material, and every milliliter of hydrochloric NM394 1-5 milligram, other is eye adjuvant and water for injection.Be dissolved in the character of acid medium according to hydrochloric acid NM394, adopt the method that main materials and auxiliary materials is prepared separately: hydrochloric acid NM394 adds appropriate water for injection, and adjust pH 5 ~ 7 is entirely molten; Mix with osmotic pressure regulator, viscosity-controlling agent, antibacterial solution etc. again, inject water to enough, after semi-finished product inspection content, pH value are qualified, through 100 DEG C of 30min circulation steam sterilizations, aseptic subpackaged, pack and get final product.
Ulifloxacin hydrochloride eye drop of the present invention can effectively infect by prevention and therapy eye sensitive organism, has following characteristics:
1, has a broad antifungal spectrum.Ulifloxacin hydrochloride eye drop has broad-spectrum antibacterial action to gram positive bacteria and gram negative bacteria, than third generation fluoroquinolone as ciprofloxacin, levofloxacin magnitude all have activity to legionella and chlamydia etc., anti-gram-negative bacteria external activity is outstanding in fluoroquinolone.Compare with levofloxacin with ciprofloxacin, Gatifloxacin, hydrochloric acid NM394 is easier to accumulation in S. aureus L-forms, escherichia coli and Pseudomonas aeruginosa cell, and short-term bactericidal action is stronger; Particularly large Pseudomonas aeruginosa is endangered for ophthalmology, be better than ciprofloxacin, levofloxacin and Moxifloxacin.
2, there is long-acting feature, longer post antibiotic effect.Ulifloxacin hydrochloride eye drop is has a broad antifungal spectrum not only, and activity in vivo is strong, has excellent bactericidal action, and internal metabolism time length also has post antibiotic effect, has long-acting feature.
3, toxic and side effects is low.Ulifloxacin hydrochloride eye drop cytotoxicity is low, move to central nervous system the advantage such as few of dividing a word with a hyphen at the end of a line, and zest is little, is adapted at eye and uses.
4, this Ulifloxacin hydrochloride eye drop is with hydrochloric acid NM394 for raw material is directly prepared, and production technology is convenient and simple, the cycle is short, steady quality, meets large-scale production needs.
In a word; this Ulifloxacin hydrochloride eye drop to the particularly ever-increasing Pseudomonas aeruginosa of drug resistance at interior gram positive bacterial infection; bioavailability is high; the ophthalmic time of staying is long, and post antibiotic effect is given prominence to, and is conducive to the abuse reducing medicine; well cost is low simultaneously for therapeutic effect; production technology is convenient and simple, the cycle is short, meets large-scale production needs, is of practical significance for the ocular infection disease for the treatment of drug resistance day by day.
Ulifloxacin hydrochloride eye drop of the present invention, with hydrochloric acid NM394 for prepared by raw material, every milliliter of hydrochloric NM394 1-5 milligram, other is suitable eye adjuvant and water for injection.Ulifloxacin hydrochloride eye drop passes through Formulation, experiment screening, and assay, stability experiment, toxicity test result etc. meet following condition:
(1) assay
This product hydrochloric acid NM394 content is the 90-110% of labelled amount.
(2) stability experiment
This product is through simulation listing packaging, and keep sample for a long time 24 months in room temperature, indices compared without significant change with 0 day.It is 2 years that effect duration fixes tentatively.
(3) pH
Ulifloxacin hydrochloride eye drop pH value is 5.0-7.0.Consider Ulifloxacin hydrochloride eye drop dissolubility, stability and antibacterial characteristics, pH value preferably 5.5 ± 0.5.
(4) toxicity test
1, hypersensitive test: to the Cavia porcellus 20 of participating in test, intramuscular injection Ulifloxacin hydrochloride eye drop 0.5ml next day of per, totally three times, then two groups are divided into, first group of lumbar injection 1ml eye drop on the 14th after injecting first, second group after injecting first jugular vein on the 21st injection 1ml drip and take liquid, observing response immediately.Result does not all occur scratching the anaphylaxiss such as nose, sneeze, perpendicular hair, tic, dyspnea, gatism, shock and death with pawl.
2, irritation test: A, to adult healthy Japan large ear rabbit 20, often organize 10 two use Ulifloxacin hydrochloride eye drop and each 2 eye drips of normal saline respectively, after certain hour, bolt looks into lacrimal secretion and conjunctival reaction situation.Result and normal saline are for comparing, and lacrimal secretion and conjunctival reaction are all normal.Administration 1,2,4,24,48,72h and 7 day, check that adult healthy Japan large ear rabbit ocular outcomes shows, conjunctiva, cornea, iris irritant reaction, Ulifloxacin hydrochloride eye drop is to eye nonirritant.B, 15 volunteers, drip 3 every day, each 2, and for three days on end, after result administration, experimenter's eye local is without uncomfortable, no abnormality seen sign.
3, subacute toxicity test: to mice 10, drip day and take twice, after continuous 15 days, checks that body weight and liver are showed no toxic reaction.
Detailed description of the invention
The present invention is further illustrated below by way of detailed description of the invention, but not as restriction of the present invention.Following Ulifloxacin hydrochloride eye drop preparation adjuvant is for meeting the requirement of eye drop eye adjuvant, and reagent is analytical pure.
Embodiment 1
Hydrochloric acid NM394 (preparation of aseptic powder raw material):
Add 5L water and 1.5L acetone in retort, add 1 kilogram of NM394 powder in 10-15 DEG C, stir lower dropping 2mol/L hydrochloric acid 1.5L, stirring reaction 1.5 hours, adds 0.05 kilogram of active carbon, stirs 20 minutes, filters decarburization; Filtrate through the filter pressing of 0.22um microporous filter membrane to sterilizing room crystallizer.Under stirring, dripping acetone 35L to separating out solid, within 4 hours, adding.Be incubated 0-5 DEG C to stir 5 hours, filter, divide secondary to wash with acetone 6L, 35 DEG C of vacuum dryings, obtain hydrochloric acid NM394 aseptic powder raw material 0.84 kilogram.
Embodiment 2
Ulifloxacin hydrochloride eye drop, every milliliter containing hydrochloric acid NM394 3mg, PVP mg, ethyl hydroxybenzoate 0.3mg.
Prescription:
Hydrochloric acid NM394 30g
Polyvinylpyrrolidone (i.e. polyvidone PVP) 400g
Ethyl hydroxybenzoate 3g
Glycerol is appropriate
Acetic acid-sodium acetate buffer (acetate buffer, pH5.5) is appropriate
Water for injection adds to 10L.
Preparation technology:
Getting hydrochloric acid NM394 30g is dissolved in 2L water for injection; Separately get PVP 0g, ethyl hydroxybenzoate 3g, glycerol 300ml is dissolved in 5L water for injection, heating for dissolving; Two liquid are merged, filters, add Acetic acid-sodium acetate buffer from filter, inject water to 10L, semi-finished product inspection content is qualified, adjust ph to 5.5, through 100 DEG C of 30min circulation steam sterilizations, is cooled to room temperature, use 0.22um filtering with microporous membrane, aseptic subpackaged, pack and get final product.
It is both water-soluble that PVP synthesizes macromolecule, is dissolved in again majority of organic solvent, toxicity very low, has excellent solubility property and physiological compatibility.Be that the Ulifloxacin hydrochloride eye drop of carrier has certain viscosity with PVP, mobility is little, instillation ophthalmic can form the thin medicine film of one deck at eyeball surface, have certain delayed release effect, the stability of prolong drug action time within the eye and raising medicine, can reduce zest, Shorten the Treatment Process, the hyperemia of rapid releasing focus and edema, medication is convenient, reduces times for spraying.
Embodiment 3
Ulifloxacin hydrochloride eye drop, finished product every milliliter is containing hydrochloric acid NM394 1mg, PVP mg, ethyl hydroxybenzoate 0.4mg.
Prescription:
Hydrochloric acid NM394 5g
Polyvinylpyrrolidone 200g
Ethyl hydroxybenzoate 2g
Glycerol is appropriate
Acetate buffer is appropriate
5% sodium hydroxide solution is appropriate
Water for injection adds to 5L.
Preparation technology:
Getting hydrochloric acid NM394 5g is dissolved in 1L water for injection; Separately get polyvinylpyrrolidone 200g, ethyl hydroxybenzoate 1.5g, glycerol 150ml is dissolved in 3L water for injection, heating for dissolving; Two liquid are merged, filter, add acetate buffer from filter, inject water to about 5L, 5% sodium hydroxide solution adjust ph to 6.5 ± 0.5, semi-finished product inspection content is qualified, through 100 DEG C of 30min circulation steam sterilizations, be cooled to room temperature, use 0.22um filtering with microporous membrane, aseptic subpackaged, pack and get final product.
Embodiment 4
Ulifloxacin hydrochloride eye drop, finished product every milliliter is containing hydrochloric acid NM394 1mg, PVP mg, ethyl hydroxybenzoate 0.3mg.
Prescription:
Hydrochloric acid NM394 10g
PVP 0g
Ethyl hydroxybenzoate 3g
Glycerol is appropriate
Acetate buffer is appropriate
Water for injection adds to 10L.
Preparation technology:
Get in the molten 2L water for injection of hydrochloric acid NM394 10g; Separately get PVP 0g, ethyl hydroxybenzoate 3g, glycerol 300ml is dissolved in 5L water for injection, heating for dissolving; Two liquid are merged, filters, add acetate buffer from filter, inject water to amount of preparation 10L, adjust ph to 5.0, through 100 DEG C of 30min circulation steam sterilizations, be cooled to room temperature, semi-finished product inspection content is qualified, use 0.22um filtering with microporous membrane, aseptic subpackaged, pack and get final product.
Embodiment 5
Ulifloxacin hydrochloride eye drop, every finished product every milliliter is containing hydrochloric acid NM394 2mg, PVP mg, ethyl hydroxybenzoate 0.3mg, glycerol 0.03ml.
Prescription:
Hydrochloric acid NM394 50g
PVP 0g
Ethyl hydroxybenzoate 3g
Glycerol is appropriate
Acetate buffer is appropriate
Water for injection adds to 10L.
Preparation technology:
Getting hydrochloric acid NM394 50g is dissolved in 2L water for injection; Separately get PVP 0g, ethyl hydroxybenzoate 3g, glycerol 300ml is dissolved in 5L water for injection, heating for dissolving; Two liquid are merged, filters, add acetate buffer from filter, inject water to amount of preparation 10L, adjust ph to 5.5 ± 0.5, through 100 DEG C of 30min circulation steam sterilizations, be cooled to room temperature, semi-finished product inspection content is qualified, use 0.22um filtering with microporous membrane, aseptic subpackaged, pack and get final product.
Embodiment 6
Ulifloxacin hydrochloride eye drop, every finished product every milliliter is containing hydrochloric acid NM394 1mg, methyl parahydroxybenzoate 0.42mg, propyl p-hydroxybenzoate 0.065mg, sodium chloride 3.8mg, glycerol 0.01ml.
Prescription:
Hydrochloric acid NM394 10g
Methyl parahydroxybenzoate 4.2g
Propyl p-hydroxybenzoate 0.65g
Sodium chloride 38g
Glycerol 100ml
Borate buffer is appropriate
Water for injection adds to 10L.
Preparation technology:
Getting hydrochloric acid NM394 10g is dissolved in 4L water for injection; Separately get methyl parahydroxybenzoate 4.2g, propyl p-hydroxybenzoate 0.65g, sodium chloride 38g, glycerol 100ml, add 5L water for injection, heating for dissolving; Two liquid are merged, filters, add borate buffer from filter, inject water to 10L, semi-finished product inspection content is qualified, and adjust ph, to 5-7, through 100 DEG C of 30min circulation steam sterilizations, is cooled to room temperature, use 0.22um filtering with microporous membrane, aseptic subpackaged, pack and get final product.
Embodiment 7
Ulifloxacin hydrochloride eye drop, every finished product every milliliter containing hydrochloric acid NM394 3mg, lysine 5mg, chlorobutanol 4.4mg, sodium chloride 6.4mg, 1,2 propylene glycol 0.22g, methylcellulose 0.3mg, lecithin 0.5mg.
Prescription:
Hydrochloric acid NM394 15g
Lysine 25g
Chlorobutanol 22g
Sodium chloride 32g
1,2 propylene glycol 1.1g
Methylcellulose 1.5g
Lecithin 2.5g
Phosphate buffer is appropriate
Water for injection adds to 5L.
Preparation technology:
Get in the water for injection that hydrochloric acid NM394 15g is dissolved in containing lysine 25g, lecithin 2.5g; Separately get recipe quantity chlorobutanol, sodium chloride, 1,2 propylene glycol, methylcellulose 1.5g are dissolved in appropriate water for injection, stirring and dissolving; Two liquid are merged, filters, add appropriate phosphate buffer, inject water to amount of preparation, adjust ph to 5.5 ± 0.5, semi-finished product inspection content is qualified, through 100 DEG C of 30min circulation steam sterilizations, is cooled to room temperature, use 0.22um filtering with microporous membrane, aseptic subpackaged, pack and get final product.
Embodiment 8
Ulifloxacin hydrochloride eye drop, every finished product every milliliter is containing hydrochloric acid NM394 2mg, lecithin 0.5mg, lysine 3mg, sodium chloride 9mg, methyl parahydroxybenzoate 0.5mg and propyl p-hydroxybenzoate 0.16mg, methylcellulose 0.35mg.
Preparation technology:
Get in the water for injection that hydrochloric acid NM394 10g is dissolved in containing lysine 15g, lecithin 2.5g; Separately get sodium chloride 45g, methyl parahydroxybenzoate 2.5g and propyl p-hydroxybenzoate 0.8g, methylcellulose 1.75g is dissolved in appropriate water for injection, stirring and dissolving; Two liquid are merged, filters, add appropriate phosphate buffer, inject water to amount of preparation 5L, adjust ph to 5.5 ± 0.5, semi-finished product inspection content is qualified, through 100 DEG C of 30min circulation steam sterilizations, is cooled to room temperature, use 0.22um filtering with microporous membrane, aseptic subpackaged, pack and get final product.
Embodiment 9
Ulifloxacin hydrochloride eye drop, every finished product every milliliter is containing hydrochloric acid NM394 1mg, lecithin 0.5mg, lysine 3mg, glucose 12 milligrams, methyl parahydroxybenzoate 0.5mg and propyl p-hydroxybenzoate 0.16mg, methylcellulose 0.35mg.
Preparation technology:
Get in the water for injection that hydrochloric acid NM394 5g is dissolved in containing lysine 15g, lecithin 2.5g; Separately get glucose 60 grams, methyl parahydroxybenzoate 2.5g and propyl p-hydroxybenzoate 0.8g, methylcellulose 1.75g is dissolved in appropriate water for injection, stirring and dissolving; Two liquid are merged, filters, add appropriate phosphate buffer, inject water to amount of preparation 5L, adjust ph to 5.5 ± 0.5, semi-finished product inspection content is qualified, through 100 DEG C of 30min circulation steam sterilizations, is cooled to room temperature, use 0.22um filtering with microporous membrane, aseptic subpackaged, pack and get final product.
Embodiment 10
Ulifloxacin hydrochloride eye drop, every finished product every milliliter is containing hydrochloric acid NM394 5mg, lecithin 0.5mg, lysine 3mg, glucose 12 milligrams, methyl parahydroxybenzoate 0.5mg and propyl p-hydroxybenzoate 0.16mg, methylcellulose 0.35mg.
Preparation technology:
Get in the water for injection that hydrochloric acid NM394 25g is dissolved in containing lysine 15g, lecithin 2.5g; Separately get glucose 60 grams, methyl parahydroxybenzoate 2.5g and propyl p-hydroxybenzoate 0.8g, methylcellulose 1.75g is dissolved in appropriate water for injection, stirring and dissolving; Two liquid are merged, filters, add appropriate phosphate buffer, inject water to amount of preparation 5L, adjust ph to 5.5 ± 0.5, semi-finished product inspection content is qualified, through 100 DEG C of 30min circulation steam sterilizations, is cooled to room temperature, use 0.22um filtering with microporous membrane, aseptic subpackaged, pack and get final product.
Embodiment 11
Ulifloxacin hydrochloride eye drop, every finished product every milliliter is containing hydrochloric acid NM394 3mg, lecithin 0.5mg, lysine 3mg, glucose 7 milligrams, 4 milligrams, sodium chloride, methyl parahydroxybenzoate 0.5mg and propyl p-hydroxybenzoate 0.16mg, methylcellulose 0.35mg.
Preparation technology:
Get in the water for injection that hydrochloric acid NM394 15g is dissolved in containing lysine 15g, lecithin 2.5g; Separately get glucose 35 grams, 20 grams, sodium chloride, methyl parahydroxybenzoate 2.5g and propyl p-hydroxybenzoate 0.8g, methylcellulose 1.75g be dissolved in appropriate water for injection, heated and stirred is dissolved; Two liquid are merged, filters, add appropriate phosphate buffer, inject water to amount of preparation 5L, adjust ph to 5.5 ± 0.5, semi-finished product inspection content is qualified, through 100 DEG C of 30min circulation steam sterilizations, is cooled to room temperature, use 0.22um filtering with microporous membrane, aseptic subpackaged, pack and get final product.
Embodiment 12
Ulifloxacin hydrochloride eye drop, every finished product every milliliter containing hydrochloric acid NM394 3mg, glucose 12 milligrams, methyl parahydroxybenzoate 0.5mg and propyl p-hydroxybenzoate 0.16mg, methylcellulose 0.35mg.
Preparation technology:
Get in the water for injection 2L that hydrochloric acid NM394 15g is dissolved in containing lysine 15g, lecithin 2.5g; Separately get glucose 35 grams, 20 grams, sodium chloride, methyl parahydroxybenzoate 2.5g and propyl p-hydroxybenzoate 0.8g, methylcellulose 1.75g be dissolved in appropriate water for injection, heated and stirred is dissolved; Two liquid are merged, filters, add appropriate phosphate buffer, inject water to amount of preparation 5L, adjust ph to 5.5 ± 0.5, semi-finished product inspection content is qualified, through 100 DEG C of 30min circulation steam sterilizations, is cooled to room temperature, use 0.22um filtering with microporous membrane, aseptic subpackaged, pack and get final product.
Embodiment 13
Ulifloxacin hydrochloride eye drop, every finished product every milliliter containing hydrochloric acid NM394 1mg, glucose 12 milligrams, 5% benzalkonium bromide 0.004ml, methylcellulose 0.35mg.
Preparation technology:
Getting hydrochloric acid NM394 5g is dissolved in water for injection 2L; Separately get glucose 60 grams, 5% benzalkonium bromide 20ml, methylcellulose 1.75g be dissolved in appropriate water for injection, heated and stirred dissolve; Two liquid are merged, filters, add appropriate phosphate buffer, inject water to amount of preparation 5L, adjust ph to 5.5 ± 0.5, semi-finished product inspection content is qualified, through 100 DEG C of 30min circulation steam sterilizations, is cooled to room temperature, use 0.22um filtering with microporous membrane, aseptic subpackaged, pack and get final product.
Embodiment 14
Ulifloxacin hydrochloride eye drop, every finished product every milliliter containing hydrochloric acid NM394 1mg, 7 milligrams, sodium chloride, 5% benzalkonium bromide 0.004ml, hydroxypropyl methylcellulose 3mg.
Preparation technology:
Getting hydrochloric acid NM394 5g is dissolved in water for injection 2L; Separately get 35 grams, sodium chloride, 5% benzalkonium bromide 20ml, hydroxypropyl methylcellulose 15g be dissolved in appropriate water for injection, heated and stirred dissolve; Two liquid are merged, filters, add appropriate phosphate buffer, inject water to amount of preparation 5L, adjust ph to 5.5 ± 0.5, semi-finished product inspection content is qualified, through 100 DEG C of 30min circulation steam sterilizations, is cooled to room temperature, use 0.22um filtering with microporous membrane, aseptic subpackaged, pack and get final product.
Embodiment 15
Ulifloxacin hydrochloride eye drop, every finished product every milliliter containing hydrochloric acid NM394 1mg, hyaluronic acid sodium 1 milligram, benzalkonium chloride 0.5mg, sodium chloride 5mg.
Preparation technology:
Getting hydrochloric acid NM394 1g is dissolved in 50 DEG C of water for injection 700ml; Separately get 5 grams, sodium chloride, benzalkonium chloride 0.5g, hyaluronic acid sodium 1g are dissolved in 200ml water for injection, 50 DEG C of heated and stirred are dissolved; Two liquid are merged, filter, cooling, adds appropriate phosphate buffer, cooling injects water to amount of preparation 1L, adjust ph to 5.5 ± 0.5, semi-finished product inspection content is qualified, through 100 DEG C of 30min circulation steam sterilizations, be cooled to room temperature, use 0.22um filtering with microporous membrane, aseptic subpackaged, pack and get final product.
Embodiment 16
Ulifloxacin hydrochloride eye drop, every finished product every milliliter containing hydrochloric acid NM394 1mg, hyaluronic acid sodium 1 milligram, thimerosal 0.01mg, sodium chloride 5mg.
Preparation technology:
Getting hydrochloric acid NM394 1g is dissolved in 50 DEG C of water for injection 700ml; Separately get 5 grams, sodium chloride, thimerosal 0.01g, hyaluronic acid sodium 1g are dissolved in 200ml water for injection, 50 DEG C of heated and stirred are dissolved; Two liquid are merged, filter, cooling, adds appropriate phosphate buffer, cooling injects water to amount of preparation 1L, adjust ph to 5.5 ± 0.5, semi-finished product inspection content is qualified, through 100 DEG C of 30min circulation steam sterilizations, be cooled to room temperature, use 0.22um filtering with microporous membrane, aseptic subpackaged, pack and get final product.
Embodiment 17
Ulifloxacin hydrochloride eye drop, every finished product every milliliter containing hydrochloric acid NM394 1mg, 7 milligrams, sodium chloride, 5% benzalkonium bromide 0.004ml, hydroxypropyl methylcellulose 3mg.
Preparation technology:
Getting hydrochloric acid NM394 5g is dissolved in water for injection 2L; Separately get 35 grams, sodium chloride, 5% benzalkonium bromide 20ml, hydroxypropyl methylcellulose 15g be dissolved in appropriate water for injection, heated and stirred dissolve; Two liquid are merged, filters, add appropriate lucky Fei Shi buffer, inject water to amount of preparation 5L, adjust ph to 5.5 ± 0.5, semi-finished product inspection content is qualified, through 100 DEG C of 30min circulation steam sterilizations, is cooled to room temperature, use 0.22um filtering with microporous membrane, aseptic subpackaged, pack and get final product.
Embodiment 18
Ulifloxacin hydrochloride eye drop, every finished product every milliliter containing hydrochloric acid NM394 1mg, 7 milligrams, sodium chloride, 5% benzalkonium bromide 0.004ml, hydroxypropyl methylcellulose 3mg.
Preparation technology:
Getting hydrochloric acid NM394 5g is dissolved in water for injection 2L; Separately get 35 grams, sodium chloride, 5% benzalkonium bromide 20ml, hydroxypropyl methylcellulose 15g be dissolved in appropriate water for injection, heated and stirred dissolve; Two liquid are merged, filters, add proper amount of acetic acid sodium-borate buffer, inject water to amount of preparation 5L, adjust ph to 5.5 ± 0.5, semi-finished product inspection content is qualified, through 100 DEG C of 30min circulation steam sterilizations, is cooled to room temperature, use 0.22um filtering with microporous membrane, aseptic subpackaged, pack and get final product.
The above embodiment only have expressed several embodiment of the present invention, and it describes comparatively concrete and detailed, but therefore can not be interpreted as the restriction to the scope of the claims of the present invention.It should be pointed out that for the person of ordinary skill of the art, without departing from the inventive concept of the premise, can also make some distortion and improvement, these all belong to protection scope of the present invention.Therefore, the protection domain of patent of the present invention should be as the criterion with claims.
Claims (4)
1. a Ulifloxacin hydrochloride eye drop, is characterized in that, with hydrochloric acid NM394 for prepared by raw material, and every milliliter of hydrochloric NM394 1-5 milligram, other is suitable eye adjuvant and water for injection; Described eye adjuvant is containing osmotic pressure regulator, viscosity-controlling agent, antibacterial, pH adjusting agent, and described osmotic pressure regulator is selected from sodium chloride, glucose, boric acid, potassium chloride, glycerol; Viscosity-controlling agent is selected from methylcellulose, polyvinyl alcohol, polyvidone, hypromellose, hyaluronic acid sodium; Antibacterial is selected from benzalkonium chloride, benzalkonium bromide, thimerosal, phenethanol, chlorobutanol, parabens; PH adjusting agent is selected from phosphate buffer, boric acid series of buffer, lucky Fei Shi buffer, acetate series of buffer, sodium acetate-borate buffer, hydrochloric acid, acetic acid, sodium hydroxide solution; Described Ulifloxacin hydrochloride eye drop pH value is 5.5 ± 0.5.
2. Ulifloxacin hydrochloride eye drop as claimed in claim 1, is characterized in that, every milliliter containing hydrochloric acid NM394 1-5 milligram, suitable eye adjuvant and water for injection; Described suitable eye adjuvant is that osmotic pressure regulator 1-20 milligram, antibacterial are appropriate, viscosity-controlling agent 0.2-0.5 milligram.
3. its preparation method of Ulifloxacin hydrochloride eye drop as claimed in claim 1, is characterized in that, comprise the following steps: hydrochloric acid NM394 adds appropriate water for injection, make entirely molten; Again with suitable eye adjuvant mixed dissolution, inject water to enough, adjust ph to 5.5 ± 0.5, after semi-finished product inspection content, pH value are qualified, through circulation steam sterilization, aseptic subpackaged, pack and get final product.
4. the preparation method of Ulifloxacin hydrochloride eye drop as claimed in claim 3, is characterized in that, comprise the following steps: get hydrochloric acid NM394 5-25g and be dissolved in 1L water for injection; Separately get polyvinylpyrrolidone 200g, ethyl hydroxybenzoate 1.5g, glycerol 150ml is dissolved in 3L water for injection, heating for dissolving; Merged by two liquid, filter, add acetate buffer solution from filter, cooling injects water to amount of preparation 5L, adjust ph to 5.5 ± 0.5, semi-finished product inspection content is qualified, through 100 DEG C of 30min circulation steam sterilizations, with 0.22 μm of filtering with microporous membrane, aseptic subpackaged, pack and get final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310738292.4A CN103735499B (en) | 2013-12-26 | 2013-12-26 | A kind of Ulifloxacin hydrochloride eye drop and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310738292.4A CN103735499B (en) | 2013-12-26 | 2013-12-26 | A kind of Ulifloxacin hydrochloride eye drop and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103735499A CN103735499A (en) | 2014-04-23 |
| CN103735499B true CN103735499B (en) | 2016-01-20 |
Family
ID=50492620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310738292.4A Active CN103735499B (en) | 2013-12-26 | 2013-12-26 | A kind of Ulifloxacin hydrochloride eye drop and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103735499B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107501298A (en) * | 2017-08-25 | 2017-12-22 | 兆科药业（合肥）有限公司 | Hydrochloric acid NM394 crystal and its production and use |
| CN107383069A (en) * | 2017-08-25 | 2017-11-24 | 兆科药业（合肥）有限公司 | Hydrochloric acid NM394 crystal and its production and use |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101003540A (en) * | 2006-01-18 | 2007-07-25 | 广州白云山制药股份有限公司广州白云山制药总厂 | Anti infectious compound and usage |
| CN101172108A (en) * | 2006-10-31 | 2008-05-07 | 江苏正大天晴药业股份有限公司 | Prulifloxacin active body injection |
| CN102198134B (en) * | 2010-03-22 | 2013-06-26 | 北京联木医药技术发展有限公司 | Use of new stable Ulifloxacin hydrochloride in preparation of anti-infection medicine |
| CN102670494B (en) * | 2012-05-22 | 2013-09-18 | 宁夏康亚药业有限公司 | Eye drop and preparation method and application thereof |
-
2013
- 2013-12-26 CN CN201310738292.4A patent/CN103735499B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103735499A (en) | 2014-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mah | Fourth-generation fluoroquinolones: new topical agents in the war on ocular bacterial infections | |
| CN101631543B (en) | Ophthalmic and otic compositions of facially amphiphilic polymers and oligomers and uses thereof | |
| KR20160147023A (en) | Compounds for treating ophthalmic diseases and disorders | |
| US10973758B2 (en) | Methods of eye treatment using therapeutic compositions containing dipyridamole | |
| US11850213B2 (en) | Ophthalmic compositions of rifamycins and uses thereof | |
| CN103735499B (en) | A kind of Ulifloxacin hydrochloride eye drop and preparation method thereof | |
| JP2011515477A (en) | Improved topical ophthalmic composition | |
| CN103705449B (en) | A kind of Uliflourxacin eye drop and preparation method thereof | |
| CN102670493B (en) | Lomefloxacin hydrochloride eye drops and preparation method and application thereof | |
| JP3502574B2 (en) | Eye ointment for treatment of eye infections | |
| WO2016196989A1 (en) | Topical composition | |
| CN105943500A (en) | Isavuconazole-containing nano-micelle antifungal solution for eyes | |
| KR101227230B1 (en) | Compositions and methods for modulating endophthalmitis using fluoroquinolones | |
| JP2016521706A (en) | Topical aqueous ophthalmic composition containing a 1H-indole-1-carboxamide derivative and its use in the treatment of eye diseases | |
| US20190231765A1 (en) | Methods for treating ocular disease using inhibitors of csf-1r | |
| Tai et al. | Corneal and scleral permeability of quinolones—a pharmacokinetics study | |
| US12042500B2 (en) | Mucoadhesive drug delivery system for ocular administration of fluoroquinolone antibiotics | |
| US20240182428A1 (en) | Prodrug of celecoxib, preparation method therefor and application thereof | |
| CN115869254A (en) | Antibiotic eye preparation and preparation method and application thereof | |
| US20110166126A1 (en) | Compositions and Methods for Modulating Endophthalmitis Using Fluoroquinolones | |
| CN102743391A (en) | Methylprednisolone or its derivative-containing externally-used composite for eyes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |